Microbiome Therapeutics News
-
Showcase
Atmo Biosciences awarded Australian Government grant to automate and scale-up manufacturing of ingestible gas-sensing capsule
Atmo Biosciences has been awarded an Australian Government Manufacturing Modernisation Fund (MMF) grant to support manufacturing automation and scale-up for the Atmo Gas-Sensing Capsule. The Round 2 MMF grants, part of the Government’s Modern Manufacturing Strategy, are for small-medium sized businesses to transform manufacturing and to support job growth and develop a more skilled ...
-
CD Genomics Unveils A Pioneering Genomics Approach—Long Amplicon Analysis (LAA) Service
CD Genomics, a trailblazing genomics and bioinformatics services provider, is delighted to announce the launch of the Long Amplicon Analysis (LAA) service, a mature genomic research method that promises to revolutionize the field. With LAA, scientists can now explore intricate genomic landscapes, facilitating groundbreaking discoveries and advancements in various branches of genomics. Long ...
By CD Genomics
-
Creative Enzymes Introduces a Range of Lactobacillus Strains with Enhanced Benefits
Creative Enzymes, a leading provider of innovative enzymes and probiotic solutions, is proud to introduce a range of Lactobacillus strains with enhanced benefits that are designed to revolutionize the way we approach gut health. This high-quality probiotic powder not only offers a wide range of health benefits but also opens up new opportunities for the food and pharmaceutical industries. In ...
-
Creative Enzymes Revolutionizes the Probiotics Industry with Bacillus Coagulans Freeze Dried Powder
Creative Enzymes, a professional enzyme provider located in New York, USA, proudly unveils its high-quality product, Bacillus Coagulans Freeze Dried Powder. This cutting-edge probiotic powder not only offers a multitude of health benefits but also ushers in unprecedented opportunities for the food and pharmaceutical industries. Bacillus Coagulans, a resilient and spore-forming bacterium, has ...
-
Simplify Your Microbiome Research with MicrobioSeq’s Microbial Biomarker Discovery Service
MicrobioSeq is the microbial genomics division on behalf of CD Genomics, headquartered in New York, USA. The product manager is pleased to announce the launch of its Microbial Biomarker Discovery service, a revolutionary solution that promises to transform microbiology research. Microbiome research has rapidly gained momentum in recent years as scientists have come to appreciate the vital role ...
By CD Genomics
-
Bened Biomedical Affiliates US Distributor, Now Bened Life
Bened Biomedical Co, LTD., the global leader in psychobiotics with clinical studies, has acquired its US distributor Oryx Biomedical, Inc., who is pioneering the translation of microbiome research into impactful biotherapeutics and is one of the earliest stage companies bringing the gut-brain axis category of probiotics to the market. Based in Taiwan and founded by Prof. Ying-Chieh Tsai, PhD, ...
-
Bened Biomedical Completes $10M Series A, Set for Expansion into US Healthcare Market
Medical probiotic leader Bened Biomedical Co., Ltd., which develops and markets neuroactive probiotic products, announced a completed Series A round of fundraising, receiving more than $10 million of capital from two prominent investors, Trans-Pacific Technology Fund (TPTF) and JAFCO Asia. With strategic support from these venture capital partners, Bened expects to rapidly expand its ...
-
Creative Proteomics Metabolomics Expands Service Offering with the Launch of Gut Microbiota Metabolomics Solution
Metabolomics, a division of Creative Proteomics, is dedicated to providing cutting-edge LC-MS-based metabolomics services for biomedical research institutions as well as biotechnological and pharmaceutical companies. Creative Proteomics Metabolomics announced the launch of the Gut Microbiota Metabolomics Service, aiming to detect the dynamic changes in enterobacterial metabolites and clearly ...
-
Lumen Bioscience Receives Broad Funding Support for Advancement of Antibiotic Alternative for Preventing Traveler’s Diarrhea
Lumen Bioscience, a clinical-stage biotechnology company developing biologic drugs for highly prevalent diseases, today announced several funding milestones supporting the development of its therapeutics to prevent serious diarrheal diseases. The first is a $5 million grant from the Bill & Melinda Gates Foundation for a second Phase 2 study of an improved anti-campylobacter therapeutic, ...
-
Sirenas and Hume Supernatural Enter Into Strategic Collaboration to Create Science-Backed Personal Care Products
Sirenas, a chemical discovery company harnessing computational metabolomics for “Natural Product” drug discovery, and Hume Supernatural, Inc. (“Hume”), a leading personal care product company, announced today that the companies have entered into a collaboration to bring new natural ingredients from diverse marine and terrestrial sources into the personal care space. The ...
By Sirenas
-
LISCure`s Phase 2 Drug Candidate Granted Orphan Drug Designation (ODD) from US FDA
LB-P8, a novel drug being developed by LISCure Biosciences, Inc. (LISCure) as a treatment for Primary Sclerosing Cholangitis (PSC), has been designated as an orphan drug by the US FDA. On December 1, 2022, the US FDA notified LISCure of the orphan drug designation of LB-P8, LISCure's microbiome novel drug, as treatment of PSC. LB-P8 is, to the best of company's knowledge, the first drug to be ...
-
Lumen Bioscience Awarded $3.6 Million by U.S. Army to Advance Low-cost, Scalable Preventative for Antibiotic-Resistant Infections
Lumen Bioscience—a clinical-stage biopharmaceutical company developing biologic drugs for highly prevalent diseases—today announced the receipt of a $3.6 million award from the Department of Defense (DoD) for advanced biomedical product development in support of Naval operations. The award from the Medical Technology Consortium (MTEC), a 501(c)(3) biomedical technology consortium ...
-
Mariola Fotin-Mleczek, PhD, has joined Ardigen’s Scientific Board to support the drug discovery process for cancer immunology therapies
Ardigen, one of the world’s leading companies that utilizes artificial intelligence (AI) algorithms for drug discovery, is proud to announce that Mariola Fotin-Mleczek, PhD, has joined Ardigen’s Scientific Board. Her knowledge and experience will support a deeper understanding of active cancer immunotherapies in the drug discovery process provided by scientific innovation. Mariola ...
By Ardigen
-
Metatranscriptome Analysis Service Is Now Available at CD Genomics
The Bioinformatics-Analysis, a subdivision of CD Genomics, provides reliable next-generation and third-generation high-throughput sequencing data analysis, comprehensive technology services, database construction, and other related data analysis services. CD Genomics provides metatranscriptome sequencing data analysis service using bioinformatics analysis platform, which can comprehensively ...
By CD Genomics
-
Synbiotic Health Announces the Expansion of their R&D and Commercial Capabilities with the Acquisition of a New Facility in Madison, Wisconsin
Synbiotic Health, a market leader in the discovery, development, and commercialization of probiotic ingredients, announced that the company has expanded its R&D and commercial capabilities with the acquisition of a 43,000 sf facility in Madison, Wisconsin. The new facility is dedicated to the development and commercialization of advanced probiotic ingredients for improved health. The Madison ...
-
Eagle Genomics Announces USD 20M First Close; Scale-up Funding to Accelerate the Application of Microbiome Science for Global ‘One Health’ Innovation
Funds to support scale-up, including continued development of AI-augmented knowledge discovery platform, the e[datascientist]™, and continued international expansion Platform business focused on bridging the current ‘translation gap’, addressing critical bottlenecks in the industrial application of microbiome science – from soil, to plant, to farm, to fork, to human, ...
-
LISCure Biosciences Announces Oral Presentation of New Drug Candidate for NASH at Upcoming AASLD The Liver Meeting 2022
LISCure Biosciences, a clinical-stage biopharmaceutical company developing microbe-oriented new drugs based on innovative technologies, today announced that a new drug candidate for NASH was selected for an oral presentation at the American Association for The Study of Liver Diseases (AASLD) The Liver Meeting 2022, to be held November 4-8 in Washington DC. As part of the presentation, LISCure ...
-
Shoreline Biome Announces Name Change to Intus Biosciences
Shoreline Biome, the developer of the industry-leading Titan-1™ microbiome research, discovery and testing platform, announced today that it has changed its name to Intus Biosciences. Intus—a Latin word for “inside”— reflects the company’s focus on making advances in health and wellbeing by working inside the bacterial microbiome. The change marks Intus ...
-
Agnieszka Blum, MD, PhD has been promoted to the Management Board of Ardigen to strengthen drug discovery expertise
Ardigen, a global leader in artificial intelligence for drug discovery, is proud to announce that Agnieszka Blum, MD, PhD has joined the company’s Board of Management. She brings with her extensive knowledge and experience in the field of Immuno-Oncology and drug discovery, which is strategic for Ardigen’s development. Agnieszka Blum, MD, PhD will continue her mission as the General ...
By Ardigen
-
Prof. Dr. med. Michael Schmitt, MHBA has joined Ardigen`s Scientific Board to support the development of AI platforms for cell therapy discovery
Ardigen, one of the world-leading companies that utilizes artificial intelligence (AI) algorithms for drug discovery, is proud to announce that Prof. Dr. Michael Schmitt, MHBA, has joined the company’s Scientific Advisory Board. His knowledge and experience will support work on artificial intelligence-based platforms, dedicated to accelerating and optimizing the discovery of novel cell ...
By Ardigen
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you